Indigenous rapid detection kit ready to detect Nipah virus with 100% accuracy: Director, ICMR-NIV
Pune: The Indian Council of Medical Research (ICMR) has developed a portable test kit for detecting Nipah virus cases with 100 per cent accuracy, which can provide results within 1- 2 hours.
According to Dr Naveen Kumar, Director, ICMR-NIV, Pune, "Based on amplification of viral gene without the need for a specialised machine at the field level. It's 100 per cent sensitive and specific."
This test can provide results in "1-2 hours". The Nipah virus is a Zoonotic virus that primarily spreads through fruit bats, and the virus has a 50% mortality rate, making it one of the most dangerous viral diseases.
The cost of the test is 250 rupees, and the name of this kit is Loop-mediated isothermal amplification (LAMP) assay for rapid detection of Nipah virus.
Meanwhile, Monoclonal antibody development is underway in collaboration with Zydus Health Sciences, Ahmedabad and Translational Health Sciences Technology Institute, Faridabad. The ICMR is also working on an indigenous vaccine for the Nipah virus.
The National Institute of Virology (NIV) is the only lab in the country that cultures the Nipah virus.
Nipah virus (NiV) is a zoonotic virus (it is transmitted from animals to humans) and can also be transmitted through contaminated food or directly between people. In infected people, it causes a range of illnesses from asymptomatic (subclinical) infection to acute respiratory illness and fatal encephalitis.
The symptoms of the Nipah virus are fever, headaches, muscle pain, vomiting, sore throat, dizziness, altered consciousness, and Atypical pneumonia.
Outbreaks of Nipah Virus Disease (NiVD) have been reported in Kerala, with the most recent one occurring in 2023 in the Kozhikode district.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
4 hours ago
- Indian Express
‘Nicotine addiction hasn't disappeared, it has simply shape-shifted'
Smokeless tobacco is the number one problem in India and there is an urgent need to strengthen laws and regulations to address it effectively,' Dr Shalini Singh, director of the Indian Council of Medical Research-National Institute of Cancer Prevention (ICMR-NICPR) and the World Health Organisation-Framework Convention on Tobacco Control (WHO-FCTC) Global Knowledge Hub on Smokeless Tobacco told The Indian Express. On the sidelines of the World Conference of Tobacco Control under way at Dublin, Dr Singh observed that globally, cigarette smoking is on the decline — especially in high-income countries, where public health regulations have tightened and consumer behavior is shifting. 'But nicotine addiction hasn't disappeared; it has simply shape-shifted. The rise of electronic nicotine delivery systems (ENDS), synthetic nicotine pouches, and 'flavoured wellness' lozenges represents a quiet but aggressive reinvention of the nicotine business. These products are marketed as cleaner, safer, and even medicinal — often using the language of 'harm reduction'. While India has banned e-cigarettes, these new delivery systems pose a serious public health risk in countries with poor implementation of regulations,' Dr Singh said. India is already home to one of the largest populations of smokeless tobacco (SLT) and bidi users globally. According to the Global Adult Tobacco Survey (GATS) 2016–17, over 199 million Indians use SLT, 72 million smoke bidis, whereas only 37 million smoke cigarettes. Less than 4 per cent of tobacco users use any cessation pharmacotherapy, and over 70 per cent quit without formal help. 'This makes India an especially vulnerable target for the tobacco industry's new nicotine expansion strategy,' Dr Singh said. Harm reduction, when implemented as part of a comprehensive cessation strategy, has clinical value. But the tobacco industry has co-opted the term 'harm reduction' to further its own interests of reduced regulation and to expand its user base. While India banned e-cigarettes in 2019 under the Prohibition of Electronic Cigarettes Act, experts said the same industry has repackaged nicotine in non-combustible, e-cigarettes adjacent forms — such as synthetic nicotine pouches and gums — often marketed as herbal, Ayurvedic, or wellness products on Indian e-commerce platforms. 'This represents not only a strategic circumvention of the e-cigarette ban but also a continuation of the industry's practice of promoting products that protect profits while presenting a facade of supporting smoking cessation,' Dr Singh added. India permits over-the-counter (OTC) sale of 2 mg nicotine gums and lozenges, based on the assumption that easier accessibility would enhance tobacco cessation efforts. The 2 mg NRT formulation, particularly when used with behavioural counselling, can play a crucial role in reducing dependence on smoking tobacco. Global evidence is clear: NRTs are most effective when used with structured counselling and support, not when taken in isolation. Many low- and middle-income countries (LMICs), including India, have NRTs in OTC markets and require integration with comprehensive cessation services. In India, the effectiveness of OTC NRT is further undermined by systemic challenges: the very low cost of smokeless tobacco (SLT) products like gutkha, khaini, and bidis; the online sales of nicotine products frequently bypass age restrictions;and the economic burden of NRT — where one week's supply often costs more than a month's worth of SLT or bidi. Without counselling support and affordability measures, OTC NRT risks becoming another market commodity rather than a true cessation aid,' Dr Singh pointed out. Long-term use of nicotine — whether through vaping, pouches, or even unsupervised NRT — poses real risks. Yet, these products are increasingly available through online platforms in India, marketed with no warning labels, no age-gating, and no evidence-based cessation claims, Dr Singh cautioned. Urgent policy priorities include banning of flavoured and industry-manufactured non-combustible nicotine products, including gums and pouches not intended for supervised cessation. There is a need to tightly regulate OTC NRT, especially in flavours and formulations attractive to youth; regulate all online sales of nicotine products with mandatory age verification, licensing, and product labelling.
Time of India
6 hours ago
- Time of India
Indigenous rapid detection kit ready to detect Nipah virus with 100% accuracy: Director, ICMR-NIV
Pune: The Indian Council of Medical Research (ICMR) has developed a portable test kit for detecting Nipah virus cases with 100 per cent accuracy, which can provide results within 1- 2 hours. According to Dr Naveen Kumar, Director, ICMR-NIV, Pune, "Based on amplification of viral gene without the need for a specialised machine at the field level. It's 100 per cent sensitive and specific." This test can provide results in "1-2 hours". The Nipah virus is a Zoonotic virus that primarily spreads through fruit bats, and the virus has a 50% mortality rate, making it one of the most dangerous viral diseases. The cost of the test is 250 rupees, and the name of this kit is Loop-mediated isothermal amplification (LAMP) assay for rapid detection of Nipah virus. Meanwhile, Monoclonal antibody development is underway in collaboration with Zydus Health Sciences, Ahmedabad and Translational Health Sciences Technology Institute, Faridabad. The ICMR is also working on an indigenous vaccine for the Nipah virus. The National Institute of Virology (NIV) is the only lab in the country that cultures the Nipah virus. Nipah virus (NiV) is a zoonotic virus (it is transmitted from animals to humans) and can also be transmitted through contaminated food or directly between people. In infected people, it causes a range of illnesses from asymptomatic (subclinical) infection to acute respiratory illness and fatal encephalitis. The symptoms of the Nipah virus are fever, headaches, muscle pain, vomiting, sore throat, dizziness, altered consciousness, and Atypical pneumonia. Outbreaks of Nipah Virus Disease (NiVD) have been reported in Kerala, with the most recent one occurring in 2023 in the Kozhikode district.
The Hindu
7 hours ago
- The Hindu
Favipiravir drug shows promise against Chandipura virus in preclinical studies by NIV
Anti-viral drug Favipiravir has been found to have the potential to provide substantial protection against the Chandipura virus in the preclinical studies conducted by the Pune-based National Institute of Virology(NIV). The Chandipura virus (CHPV) is endemic in central India and symptoms include high fever and seizures. The infection also induces encephalitis. Studies on mice have shown that Favipiravir can reduce viral load and improve survival rates in infected animals, Naveen Kumar, director of NIV, which is under the Indian Council of Medical Research (ICMR), told PTI. The virus was identified during 1965 in Maharashtra from clinical samples of febrile cases. The first significant outbreak was recorded in 2003 in Telangana, which was then part of Andhra Pradesh. It infected over 300 children with more than 50 per cent fatality. Cases were also reported from Vidarbha region of Maharashtra, Telangana and Gujarat between 2003 and 2007. Even 2007 onwards sporadic cases from endemic regions were reported. In 2024, a major outbreak was reported from Gujarat and adjoining areas of Maharashtra which the WHO described as the largest outbreak in the past 20 years. It emerged to be a major threat for the paediatric population with 64 laboratory confirmed cases of the infection reported from Gujarat (61 cases) and adjoining areas, r Vijay Bondre, senior scientist at NIV, said. The outbreak was investigated by the National Joint Outbreak Response Team, Dr Bondre said. "The NIV has been working toward identifying potential anti-virals against CHPV. In the search after testing multiple anti-virals, Favipiravir has been identified to give substantial protection against the Chandipura virus infection which has also been established in the preclinical trials in the laboratory," explained Dr Kumar. So far the findings suggest that Favipiravir could be a potential therapeutic option for these infections, he said. "Clinical trials on humans are yet to be carried out to confirm its efficacy and safety in humans," Dr Kumar stated. Dr Bondre said before proceeding to testing on human, the efficacy of the drug against CHPV on animals will be re-established at another organisation - ICMR-National Animal Research Facility for Biological research. This will take another seven to eight months. Currently, the infection is managed through symptomatic treatment and there is no particular drug which is used for its treatment. In addition to it, the NIV has initiated research to develop a vaccine candidate against CHPV. The research will be of great help to the nation to minimise the high fatality due this infection among children, Dr Kumar said. The CHPV is a member of Rhabdoviridae family and is transmitted by arthropod vectors, most probably sand flies. Vector control, hygiene and awareness are the only measures available against the disease. 'The disease affects mostly children under 15 years of age and can present with a febrile illness that may progress to convulsions, coma and in some cases may result in death, Dr Bondre said.
